Johnson & Johnson
Latest Johnson & Johnson News and Updates
Earnings ReportBehind the Major Drivers of JNJ’s Medical Device Growth
Johnson & Johnson (JNJ) reported Medical Devices segment sales of ~$6.7 billion in 2Q17, compared with $6.4 billion in 2Q16. Earnings ReportAnalysts’ Latest Recommendations for Johnson & Johnson
Johnson & Johnson (JNJ) missed Wall Street analysts’ revenue estimates in 1Q17. It reported revenue of $17.8 billion in the quarter. Earnings ReportNovartis’s 2Q17 Earnings: Analyst Estimates
Novartis is set to release its 2Q17 earnings on July 18, 2017. Analysts estimate EPS (earnings per share) of $1.18 and revenues of $12.3 billion. Company & Industry OverviewsBydureon Auto-Injector May Boost the Drug’s Sales in Future Years
The combined product sales of Bydureon and Byetta globally in 1Q17 was ~$199 million, which represents 1% YoY growth on a reported basis. Company & Industry OverviewsFarxiga Could See Robust Demand in International Markets in 2017
In 1Q17, AstraZeneca’s (AZN) Farxiga reported sales of $42 million in emerging markets, which equals year-over-year growth of ~100% on a reported basis. Company & Industry OverviewsFarxiga Expected to Drive AstraZeneca’s Performance in Diabetes Segment
In 1Q17, AstraZeneca’s leading sodium-glucose co-transporter 2 (or SGLT2) therapy for type-2 diabetes, Farxiga, reported revenues close to $270 million. This represents YoY growth of ~25% on a constant currency basis. Company & Industry OverviewsWhat We Can Expect from Eli Lilly and Company in 2Q17
A look at Eli Lilly and Company Headquartered in Indianapolis, Indiana, Eli Lilly and Company (LLY) is a US pharmaceutical company focused on human pharmaceuticals and animal health. Stock price performance Eli Lilly’s stock price has fallen ~4.4% in 2Q17. However, the stock price had risen 10.9% year-to-date as of July 7, 2017. Analysts’ recommendations Wall […] Company & Industry OverviewsMerck & Co.’s Animal Health Segment’s 1Q17 Revenues
The global revenues from Merck’s Animal Health business totaled $939 million during 1Q17—13% growth over 1Q16. Company & Industry OverviewsMerck’s Immunology and Cardiovascular Franchise in 1Q17
The combined revenues for Zetia and Vytorin fell 35% to $575 million in 1Q17, compared to $889 million in 1Q16. Company & Industry OverviewsPfizer’s Segment Performance in 1Q17
Pfizer Innovative Health contributed $7.4 billion, or about 58.0% of Pfizer’s total revenues in 1Q17. MiscellaneousComparing Growth and Value Stock Sectors
The SPDR S&P 500 Growth ETF (SPYG) has generated a YTD return of 13.3% versus 4.3% from the SPDR S&P 500 Value ETF (SPYV). Company & Industry OverviewsAnalyzing Bristol-Myers Squibb’s Valuation on June 20
As of June 20, 2017, Bristol-Myers Squibb was trading at a forward PE multiple of ~18.0x—compared to the industry average of 16.0x. Company & Industry OverviewsMedtronic’s Agreement Will Expand the Use of Its Tyrx Envelopes
Medtronic’s (MDT) Tyrx envelope is an antibacterial and fully-absorbable device that helps prevent surgical site infections. Company & Industry OverviewsThis Product Pipeline Brings Hope for AbbVie’s Future Growth
AbbVie (ABBV) has a focused immunology pipeline in order to address various dermatologic and gastrointestinal conditions. Company & Industry OverviewsUnderstanding Pfizer’s 1Q17 Performance by Geography
Pfizer (PFE) reported a 2% decline in revenues to ~$12.8 billion for 1Q17, as compared to $13.0 billion in 1Q16. Company & Industry OverviewsBehind Pfizer’s Business Segments in 1Q17
Pfizer’s Innovative Health segment contributes ~58% of PFE’s total revenues and reported an operational growth of 6% to $7.4 billion for 1Q17. Company & Industry OverviewsZimmer Biomet’s Capital Allocation Strategy to Create Value
In February 2016, Zimmer Biomet authorized up to $1.0 billion of the company’s common stock for share repurchases, all of which remains authorized to date. Company & Industry OverviewsInside Novartis’s Generics Business Now
Sandoz is also a leader in differentiated generics. Its contribution made up ~21% of Novartis’s total revenues in 1Q17. Company & Industry OverviewsEli Lilly’s Business Segments’ Performance in 1Q17
Elanco, Eli Lilly’s Animal Health business, reported growth of 2% to $769.4 million during 1Q17. Company & Industry OverviewsJohnson & Johnson’s Business Segments in 1Q17
Johnson & Johnson’s business includes three segments: Pharmaceuticals, Consumer, and Medical Devices. Company & Industry OverviewsHow AstraZeneca’s Oncology Segment Performed in 1Q17
AstraZeneca’s (AZN) Oncology segment has consistently reported revenue growth over the last few years, and it’s one of the company’s key areas of focus. Company & Industry OverviewsAstraZeneca’s Segment-by-Segment Performance in 1Q17
AstraZeneca’s (AZN) business is separated into four segments: Respiratory, Cardiovascular and Metabolic Diseases (or CVMD), Oncology, and Other. Company & Industry OverviewsPerformance of Sanofi’s Established Prescription Products in 1Q17
Revenues from Sanofi’s Established Prescription Products rose 0.6% at constant exchange rates during 1Q17 and reported revenues of ~2.6 billion euros in 1Q17. Macroeconomic AnalysisIs Medical Technology Driving the US Healthcare Industry?
The US medical device industry is a global leader. Its market was valued at ~$140 billion for 2016. It represents ~45% of the global market. Company & Industry OverviewsKyprolis Could Significantly Drive Amgen’s Revenue Growth in 2017
Amgen’s (AMGN) Kyprolis has gained considerable market share in second-line multiple myeloma (or MM) indication since its launch in 2012. Earnings ReportWhat Do Analysts Expect from Merck’s 1Q17 Earnings?
Merck and Co. (MRK) will release its 1Q17 earnings on May 2, 2017. Analysts’ estimates show EPS of $0.83 on revenues of $9.25 billion for 1Q17. Earnings ReportWhy Novartis’s 1Q17 Revenues Missed Analysts’ Estimates
Novartis (NVS) released its 1Q17 earnings on April 25, 2017, reporting a 25.0% rise in revenues at constant exchange rates compared to 1Q16. Earnings ReportWhat Analysts Predict for AstraZeneca’s 1Q17 Earnings
Analysts estimate AstraZeneca will post EPS (or earnings per share) of $0.40 and revenues of $5.4 billion in 1Q17. Macroeconomic AnalysisThe Hybrid US Healthcare System: An Overview
The US healthcare system is unique in the developed world as it lacks a uniform system and, according to Emanuel, had been largely inefficient before Obamacare. Company & Industry OverviewsThese Pfizer Products Saw Declining Revenues in 2016
The overall share of revenues for the Essential Health Products business fell marginally to 44.7% of the total revenues for 2016 from 45.2% of the total revenues for 2015. Company & Industry OverviewsWhy Sanofi’s Consumer Healthcare and Generics Segment Still Matters
Sanofi’s (SNY) Consumer Healthcare segment reported a 1.6% YoY (year-over-year) fall in revenues at 3.33 billion euros (about $3.56 billion) in 2016. Company & Industry OverviewsNovartis Expects to Restore Alcon’s Profitability in the Future
Novartis (NVS) has focused its efforts on improving its customer service levels and entering into lucrative partnering deals to boost profitability for its Alcon business. Company & Industry OverviewsWhat Wall Street Analysts Are Saying about Eli Lilly
Eli Lilly (LLY) reported EPS (earnings per share) of $2.58 on revenue of $21.2 billion in 2016, compared to EPS of $2.26 on revenue of $20.0 million in 2015. Company & Industry OverviewsAre Sanofi’s Established Prescription Products Adding Up?
Sanofi’s (SNY) Established Prescription Products segment contributed nearly 30.5% of the company’s total revenues in 2016. Company & Industry OverviewsHow Does Pfizer’s Valuation Compare to Peers?
Pfizer (PFE) reported an 8% increase in revenues to $52.8 billion for 2016 as compared to $48.9 billion for 2015. Company & Industry OverviewsBausch & Lomb Continues to be Key Growth Driver for Valeant
Bausch & Lomb projections Valeant Pharmaceuticals expects its Bausch & Lomb/International segment to grow at a CAGR (compound average growth rate) of 4%–6% between 2017 and 2020. In 2017, the company expects the segment to grow 5%–7% after adjusting for foreign exchange fluctuations and the impact of impending patent expiries. In 2017, the segment is also expected […] Company & Industry OverviewsJohnson & Johnson’s Business Segment Performance
Johnson & Johnson’s Medical Devices segment contributed nearly 35% to the company’s total revenues. Company & Industry OverviewsHow Gilead’s Other Products Fared in 2016
The oncology portfolio includes the drug Zydelig, which is used in combination with rituximab for the treatment of chronic lymphocytic leukemia (or CLL). Company & Industry OverviewsAstraZeneca’s Other Products Segment Is Losing Market Share
For 2016, Synagis reported 2% growth at constant exchange rates, following its 14% growth in sales in the US. Company & Industry OverviewsChart in Focus: Performance of AstraZeneca’s Growth Platforms in 2016
AstraZeneca’s (AZN) Respiratory Product sales fell 3% at constant exchange rates to ~$4.8 billion during fiscal 2016. Company & Industry OverviewsThese Prescription Products Matter to Sanofi’s Growth
Sanofi’s (SNY) established prescription products contributed nearly 28.9% of the company’s total 4Q16 revenues. Earnings ReportAnalysts Expect Negative Growth for Novartis in 4Q16
Analysts expect an ~1.1% decline in Novartis’s (NVS) 4Q16 revenues to ~$12.4 billion following the effects of the acquisition and divestiture of several products. Company & Industry OverviewsJohnson & Johnson’s Expandable Cage Acquisition to Accelerate the Spine Division
On January 3, DePuy Synthes, a subsidiary of Johnson & Johnson (JNJ), entered into an asset purchase and development agreement with Interventional Spine. Company & Industry OverviewsInside the Latest Capability Advancement in Johnson & Johnson’s Orthopedics
On January 9, JNJ’s Medical Device division announced its Orthopedic Episode of Care Approach, a data-driven program that will accelerate value-based care. Company & Industry OverviewsExploring GlaxoSmithKline’s Business Segments
GlaxoSmithKline’s (GSK) business is divided into three business segments: Pharmaceuticals, Vaccines, and Consumer Health. Company & Industry OverviewsGlaxoSmithKline’s Revenue Trend
GlaxoSmithKline reported a rise of 23% in its 3Q16 revenue. The company met Wall Street analysts’ consensus 3Q16 estimates for revenue and earnings per share. Company & Industry OverviewsThe Competitive Landscape for Enbrel
Amgen (AMGN) launched Enbrel in the US in 1998. It became a major success for Amgen in no time and recorded $5.4 billion sales in 2015. Company & Industry OverviewsJohnson & Johnson’s Revenue Trend in 3Q16
In 3Q16, Johnson & Johnson’s (JNJ) top line rose 4.2% to ~$17.8 billion, driven by 4.3% operational growth in revenues. Company & Industry OverviewsAbbVie Plans to Launch Psoriasis Therapy Risankizumab in 2019
AbbVie (ABBV) has completed enrollment in its Phase 3 pivotal trials testing investigational therapy risankizumab as a treatment option for psoriasis. Earnings ReportHere’s What’s Driving Medtronic’s MITG Segment
Of Medtronic’s ~$7.3 billion in worldwide revenues in fiscal 2Q17, ~$2.5 billion came from Medtronic’s MITG segment, representing ~34% of the company’s total revenues.